These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 16372881

  • 1. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ.
    Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
    [Abstract] [Full Text] [Related]

  • 2. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF.
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [Abstract] [Full Text] [Related]

  • 3. Review of current preclinical testing strategies for bacterial vaccines.
    Falk LA, Chandler DK, Richman P.
    Dev Biol Stand; 1998 Mar; 95():25-9. PubMed ID: 9855411
    [Abstract] [Full Text] [Related]

  • 4. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS, Griffiths E.
    Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863
    [Abstract] [Full Text] [Related]

  • 5. Nonclinical safety assessment of vaccines and adjuvants.
    Wolf JJ, Kaplanski CV, Lebron JA.
    Methods Mol Biol; 2010 Feb; 626():29-40. PubMed ID: 20099119
    [Abstract] [Full Text] [Related]

  • 6. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM, Grewal IS.
    Handb Exp Pharmacol; 2008 Feb; (181):19-44. PubMed ID: 18071940
    [Abstract] [Full Text] [Related]

  • 7. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V, Baylor NW.
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [Abstract] [Full Text] [Related]

  • 8. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS, Griffiths E.
    Methods Mol Med; 2006 May; 127():363-74. PubMed ID: 16988466
    [Abstract] [Full Text] [Related]

  • 9. Pharmaceutical excipient development: the need for preclinical guidance.
    Baldrick P.
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
    [Abstract] [Full Text] [Related]

  • 10. The presence of drug in control samples during toxicokinetic investigations--a Novartis perspective.
    Nicholls I, Kolopp M, Pommier F, Scheiwiller M.
    Regul Toxicol Pharmacol; 2005 Jul; 42(2):172-8. PubMed ID: 15885865
    [Abstract] [Full Text] [Related]

  • 11. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 12. Stability evaluation of vaccines: WHO approach.
    Knezevic I.
    Biologicals; 2009 Nov; 37(6):357-9; discussion 421-3. PubMed ID: 19729320
    [Abstract] [Full Text] [Related]

  • 13. Study designs for the nonclinical safety testing of new vaccine products.
    Forster R.
    J Pharmacol Toxicol Methods; 2012 Jul; 66(1):1-7. PubMed ID: 22561062
    [Abstract] [Full Text] [Related]

  • 14. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
    Hondeghem LM.
    Eur J Pharmacol; 2008 Apr 14; 584(1):1-9. PubMed ID: 18304526
    [Abstract] [Full Text] [Related]

  • 15. Pharmacogenomics in the preclinical development of vaccines: evaluation of efficacy and systemic toxicity in the mouse using array technology.
    Regnström KJ.
    Methods Mol Biol; 2008 Apr 14; 448():447-67. PubMed ID: 18370242
    [Abstract] [Full Text] [Related]

  • 16. Regulation and review of DNA vaccine products.
    Smith HA.
    Dev Biol (Basel); 2000 Apr 14; 104():57-62. PubMed ID: 11713825
    [Abstract] [Full Text] [Related]

  • 17. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J, Egan W, Vicari G, Furesz J, Schild G.
    Biologicals; 2007 Apr 14; 35(2):107-13. PubMed ID: 16882459
    [Abstract] [Full Text] [Related]

  • 18. Goals of stability evaluation throughout the vaccine life cycle.
    Krause PR.
    Biologicals; 2009 Nov 14; 37(6):369-78; discussion 421-3. PubMed ID: 19775911
    [Abstract] [Full Text] [Related]

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 14; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 20. Low levels of extraneous agents in vaccine starting materials.
    Rouby JC.
    Biologicals; 2010 May 14; 38(3):354-7. PubMed ID: 20347331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.